With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.


  • September 17, 2021SNMMI Shares Latest Advances in Nuclear Medicine with Patient Audience
    SNMMI’s 10th Annual Patient Education Day drew more than 220 patients, caregivers, and advocates, providing insights into the role of nuclear medicine and molecular imaging in disease diagnosis, staging, and treatment.
  • September 2, 2021This Month in JNM
    In September JNM: Editor’s Page: JNM impact factor reaches a new milestone … Discussions with leaders: Caius Radu … State of the Art: Image-Guided HIFU in nuclear medicine … Hot Topics: Cardiac PET and the future … Continuing Education: Pheochromocytoma and paraganglioma … Focus on MI: Current clinical pretargeting … Issues and Controversies: Diversity in nuclear medicine. Featured: Pretargeted immuno-PET in MTC … 68Ga-BMS-986192 for PD-L1 PET … and more.
  • August 4, 2021SNMMI Participates in "ACGME Equity Matters" Initiative
    SNMMI is proud to announce its partnership in ACGME Equity Matters, a new initiative that introduces a framework for continuous learning and process improvement in the areas of diversity, equity, and inclusion (DEI) and anti-racism practices.
  • August 2, 2021This Month in JNM
    In August JNM: Perspectives on Cutting-Edge Clinical Trials … Hot Topics: Targeted radionuclide therapy trials … Editorial: 18F-FDG for inflammation and infection … Featured articles: 18F-Enzalutamide for androgen expression … 18F-Fluciclovine and radiotherapy decisions … and more.
  • July 27, 2021Topical Molecular Imaging Tracer Enables Real-Time Detection of Cervical Cancer
    With the help of a topical fluorescent imaging agent, cervical cancer can be identified by physicians with a hand-held microscope, according to research published in the July issue of JNM.
  • July 26, 2021SNMMI Comments on CURES 2.0 Proposal
    When Reps. Upton and DeGette requested comment on their 21st Century Cures 2.0 proposal, we listened. The bill aims to continue the acceleration of the discovery, development, and delivery of 21st century cures. The coalition's letter urged Congress to use this opportunity to expand Medicare beneficiary access to diagnostic radiopharmaceuticals.
  • July 22, 2021Novel Imaging Agent Identifies Biomarker for Iron-Targeted Cancer Therapies
    A new radiotracer that detects iron in cancer cells has proven effective, opening the door for the advancement of iron-targeted therapies for cancer patients.
  • July 15, 2021The Journal of Nuclear Medicine Spotlights the Future of Nuclear Endocrinology
    A new JNM supplement focuses on nuclear endocrinology, including novel approaches and updates on imaging for hyperparathyroidism, thyroid nodules, thyrotoxicosis, adrenal masses, brown adipose tissue, hyperinsulinism, pituitary adenomas, and more.

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities.  Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.